Market Overview:
The global glycogen metabolism disease market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of glycogen storage diseases, rising awareness about these diseases, and advancements in treatment options. The global glycogen metabolism disease market is segmented by type, application, and region. By type, the market is divided into OTC drugs and Rx drugs. By application, the market is classified into hospital and retail pharmacy segments. Geographically, it is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (Japan China India Australia South Korea) and Middle East & Africa (Saudi Arabia UAE Qatar South Africa). Some of the key players operating in this market are Shire plc., Sanofi SPA,, Pfizer Inc., GlaxoSmithKline plc., Merck & Co.
Product Definition:
Glycogen metabolism disease is a disorder that affects how the body breaks down and uses glycogen, a type of sugar. This disorder can prevent the body from converting glycogen into energy, leading to muscle weakness and other problems.
OTC:
OTC stands for Over-the-Counter and is a generic term used to define products that are sold without a prescription. OTC drugs can be easily purchased from local stores, convenience stores or online retailers. The major factor contributing to the growth of this market is its wide range of applications in disease treatment as compared to prescription drugs which have limited use in certain diseases due to their strong drug interactions with the central nervous system.
Rx Drugs:
Rx drugs and it's usage in glycogen metabolism disease market is expected to grow at a significant rate during the forecast period. The growth of this market can be attributed to factors such as increasing prevalence of diabetes, growing awareness about GSD among patients & physicians, rising expenditure on R&D for rare diseases and increasing demand for effective treatment options.
Application Insights:
The retail pharmacy segment held the largest market share of over 70% in 2017. The growing demand for fast-acting solutions to treat life-threatening conditions is expected to be a major factor driving the segment growth during the forecast period. In addition, increasing awareness about glycogen metabolism diseases among consumers is anticipated to further drive growth.
Hospital was estimated as the second largest revenue generating segment owing to rising incidence of life-threatening conditions such as hypoglycemia and hyperglycemia caused due to improper liver and muscle function among other factors such as genetic disorders or diet deficiency which requires hospitalization for treatment. This trend is expected continue over next few years due Glycogenosis Type III which has been reported only in rare cases thus far with less than 10 recorded worldwide occurrences till date accordingto National Library of Medicine (NLM).
Regional Analysis:
North America accounted for the largest share of the global market in 2017. The region is expected to maintain its dominance during the forecast period due to high prevalence of obesity and diabetes, increasing adoption of healthy lifestyles, presence of key manufacturers such as Pfizer Inc., and rising awareness about glycogen storage diseases. In addition, growing demand for sports drinks among active individuals is anticipated to further fuel growth over the coming years.
Asia Pacific glycogen metabolism disease market is expected to grow at a lucrative rate during the forecast period owing to factors such as improving healthcare infrastructure & availability; rising disposable income; increase in consumer awareness regarding treatment options; and an increase in retail pharmacies & hospital pharmacies dispensing medicines OTC products leading toward increased sales volume thus fueling growth over this period.
Growth Factors:
- Increasing prevalence of obesity and diabetes
- Growing awareness about the benefits of glycogen metabolism disease treatment
- Technological advancements in glycogen metabolism disease treatment methods
- Rising demand for personalized medicine for glycogen metabolism disease treatment
- increasing funding for research and development in the field of glycogen metabolism diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Glycogen Metabolism Disease Market Research Report
By Type
OTC, Rx Drugs
By Application
Hospital, Retail Pharmacy
By Companies
Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
215
Number of Tables & Figures
151
Customization Available
Yes, the report can be customized as per your need.
Global Glycogen Metabolism Disease Market Report Segments:
The global Glycogen Metabolism Disease market is segmented on the basis of:
Types
OTC, Rx Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Novartis
- Takeda Pharmaceutical
- Astra Zeneca
- Boehringer Ingelheim
- KOWA
- Kythera
- Fuji yakuhin
- LG Life Science
- Metsubishi Tanabe Pharma
Highlights of The Glycogen Metabolism Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- OTC
- Rx Drugs
- By Application:
- Hospital
- Retail Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glycogen Metabolism Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glycogen metabolism disease is a disorder of the body's ability to break down glycogen and use it for energy. This can lead to problems with muscle function, heart health, and even death. There are several different types of glycogen metabolism diseases, each with its own set of symptoms.
Some of the major players in the glycogen metabolism disease market are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma.
The glycogen metabolism disease market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glycogen Metabolism Disease Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Glycogen Metabolism Disease Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Glycogen Metabolism Disease Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Glycogen Metabolism Disease Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Glycogen Metabolism Disease Market Size & Forecast, 2020-2028 4.5.1 Glycogen Metabolism Disease Market Size and Y-o-Y Growth 4.5.2 Glycogen Metabolism Disease Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 OTC
5.2.2 Rx Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glycogen Metabolism Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glycogen Metabolism Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 OTC
9.6.2 Rx Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 OTC
10.6.2 Rx Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 OTC
11.6.2 Rx Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 OTC
12.6.2 Rx Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 OTC
13.6.2 Rx Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glycogen Metabolism Disease Market: Competitive Dashboard
14.2 Global Glycogen Metabolism Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Novartis
14.3.3 Takeda Pharmaceutical
14.3.4 Astra Zeneca
14.3.5 Boehringer Ingelheim
14.3.6 KOWA
14.3.7 Kythera
14.3.8 Fuji yakuhin
14.3.9 LG Life Science
14.3.10 Metsubishi Tanabe Pharma